Having trouble accessing articles? Reset your cache.

Cypress ends Savella co-promotion, restructures

Cypress Bioscience Inc. (NASDAQ:CYPB) discontinued co-promotion of fibromyalgia drug Savella milnacipran in the U.S. with partner Forest Laboratories Inc. (NYSE:FRX)

Read the full 208 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE